SIGA Technologies to Host Business Update Call
NEW YORK, March 4, 2025 — SIGA Technologies, Inc. (NASDAQ: SIGA), a prominent player in the pharmaceutical industry, is gearing up for an essential webcast and conference call aimed at providing meaningful updates to stakeholders. This event is set for 4:30 P.M. ET on Tuesday, March 11, 2025, featuring insights from key executives such as Diem Nguyen, the Chief Executive Officer, and Daniel Luckshire, the Chief Financial Officer.
Accessing the Conference Call
Listening to the call will be straightforward for both domestic and international audiences. Those in the U.S. can join by dialing 1-800-717-1738, while international participants can connect via 1-646-307-1865. To enhance the experience, SIGA will provide a live webcast accessible from their official website in the Investor Relations section. Attendees should prepare to log in approximately 5-10 minutes before the scheduled start time to ensure a smooth connection.
Replaying the Meeting
For those unable to attend the live session, a replay will be available for two weeks. This can be accessed by calling 1-844-512-2921 domestically or 1-412-317-6671 internationally, using the conference ID: 1152574. The archived webcast can also be found in the Investor Relations section of the company’s website, allowing for convenient viewing at any time.
About SIGA Technologies
SIGA Technologies has established itself as a leader in developing groundbreaking medicines and countermeasures targeting infectious diseases. With a robust focus on orthopoxviruses, the company works tirelessly to mitigate the risks presented by severe infectious diseases, whether they arise naturally, accidentally, or even intentionally. Through close partnerships with various governmental bodies and public health organizations, SIGA is committed to fostering a healthier and safer world.
The company's flagship product, TPOXX (tecovirimat), is a critical antiviral approved in both the U.S. and Canada for treating smallpox and has been authorized in Europe, the UK, and Japan for similar uses, including treatments for mpox (monkeypox) and other complications. This innovative product reflects SIGA's dedication to public health and their strategic role in controlling outbreaks of serious diseases.
Contact Information
To promote transparency and open communication, SIGA encourages inquiries from both investors and media representatives. Interested parties can reach out to Suzanne Harnett at sharnett@siga.com. For investor relations, connect with Jennifer Drew-Bear from the Edison Group at Jdrew-bear@edisongroup.com, or reach Holly Stevens from Berry & Company at hstevens@berrypr.com.
Frequently Asked Questions
What is the purpose of SIGA's upcoming conference call?
The conference call aims to provide important business updates and insights from top executives, fostering communication with stakeholders.
How can I join the SIGA conference call?
Participants can join the call by dialing the designated numbers for domestic or international callers, or by accessing the live webcast via SIGA's website.
Will there be a replay available?
Yes, a replay of the call will be available for two weeks after the live event, allowing interested parties to listen at their convenience.
What is TPOXX?
TPOXX (tecovirimat) is SIGA's primary antiviral product, approved for the treatment of smallpox and authorized for use against other related infections.
Who can I contact for more information about SIGA?
For inquiries, you can reach out to various representatives at SIGA via the provided email addresses for investor and media communications.
